Display options
Cite
Kimmelman J. Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. Nat Rev Clin Oncol. 2020;17(2):125-126doi: 10.1038/s41571-019-0312-3.
Kimmelman, J. (2020). Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. Nature reviews. Clinical oncology, 17(2), 125-126. https://doi.org/10.1038/s41571-019-0312-3
Kimmelman, Jonathan. "Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'." Nature reviews. Clinical oncology vol. 17,2 (2020): 125-126. doi: https://doi.org/10.1038/s41571-019-0312-3
Kimmelman J. Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. Nat Rev Clin Oncol. 2020 Feb;17(2):125-126. doi: 10.1038/s41571-019-0312-3. PMID: 31857690.
Copy Download .nbib Format: NLM
Share it on

Nat Rev Clin Oncol. 2020 Feb;17(2):125-126. doi: 10.1038/s41571-019-0312-3.

Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'.

Nature reviews. Clinical oncology

Jonathan Kimmelman

Affiliations

  1. Studies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada. [email protected].

PMID: 31857690 DOI: 10.1038/s41571-019-0312-3

[No abstract available.]

References

  1. Kimmelman, J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nat. Rev. Clin. Oncol. 16, 719–720 (2019). - PubMed
  2. Burris, H. A. Correcting the ASCO position on phase I clinical trials in cancer. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-019-0311-4 (2019). - PubMed
  3. Kimmelman, J. Is participation in cancer phase I trials really therapeutic? J. Clin. Oncol. 35, 135–138 (2016). - PubMed
  4. Kimmelman, J. & Federico, C. Consider drug efficacy before first-in-human trials. Nature 542, 25–27 (2017). - PubMed
  5. National Cancer Institute.NCI Informed Consent Template. cancer.gov https://ctep.cancer.gov/protocolDevelopment/informed_consent.htm (2019). - PubMed

MeSH terms

Publication Types